Distributed intraclot thrombolysis: mechanism of accelerated thrombolysis with encapsulated plasminogen activators

Journal of Thrombosis and Haemostasis : JTH
J K LeachE A O'Rear

Abstract

The delivery of encapsulated plasminogen activators has demonstrated enhanced thrombolysis in vivo in several models. The mechanism of such improvement has not previously been established. We explored in vitro the mechanism by which microencapsulation of streptokinase in polymeric microparticles accelerates clot digestion and reduces reperfusion times by as much as an order of magnitude in vivo. The efficacy of microencapsulated streptokinase (MESK) was directly compared with identical dosages of unencapsulated streptokinase (FREE SK) at three initial pressure drops using clots formed of plasma or whole blood in 0.2-cm inner diameter glass capillary tubes. MESK demonstrated accelerated flow restoration compared with FREE SK for each condition in plasma (23.8 +/- 4.5% faster) and whole blood clots (17.2 +/- 9.2% faster). Images collected by light microscopy show sites of thrombolysis internal to the clot only with MESK while the spatial distribution of fluorescently labeled streptokinase by confocal microscopy confirms greater penetration of the encapsulated agent compared with unencapsulated streptokinase. Digestion thus proceeds in three dimensions rather than restricted to a two-dimensional lysis front. The improved clot pene...Continue Reading

References

Dec 1, 1989·Proceedings of the Society for Experimental Biology and Medicine·P D NguyenB M Fung
Jul 7, 2001·Science·R Langer
Aug 9, 2001·Journal of Endovascular Therapy : an Official Journal of the International Society of Endovascular Specialists·S AtarR J Siegel
Nov 8, 2001·Journal of Vascular and Interventional Radiology : JVIR·J J Bookstein, F L Bookstein
Aug 22, 2003·The New England Journal of Medicine·Henning R AndersenUNKNOWN DANAMI-2 Investigators

❮ Previous
Next ❯

Citations

Jun 4, 2013·Journal of Thrombosis and Thrombolysis·Hai-jiang JinJi-wei Zhang
Sep 12, 2008·Applied Biochemistry and Biotechnology·Jintian HeHouyan Song
May 10, 2013·Nanomedicine·Anna N Ilinskaya, Marina A Dobrovolskaia
Jun 16, 2015·Journal of Thrombosis and Haemostasis : JTH·S AbsarF Ahsan
Jan 10, 2012·International Journal of Pharmaceutics·Bhuvaneshwar VaidyaSuresh P Vyas
Oct 20, 2011·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Bhuvaneshwar VaidyaSuresh P Vyas
Feb 17, 2009·Thrombosis Research·George J ShawChristy K Holland
Dec 15, 2015·Materials Science & Engineering. C, Materials for Biological Applications·Balakrishnan SivaramanAnand Ramamurthi
Mar 12, 2016·Pharmaceutical Research·Hoai X Nguyen, Edgar A O'Rear
Aug 31, 2004·Journal of Thrombosis and Haemostasis : JTH·J W Weisel, J-P Collet
Feb 22, 2013·Journal of Biomedical Materials Research. Part a·Hoai X Nguyen, Edgar A O'Rear
Jul 19, 2011·IUBMB Life·Ronald Carnemolla, Vladimir R Muzykantov
Dec 11, 2007·Ultrasonics Sonochemistry·Cedric GoldenstedtCyril Lafon
Jan 25, 2017·Frontiers of Medicine·Melvin E Klegerman
Apr 9, 2014·Bioorganicheskaia khimiia·L I MukhametovaK B Gershkovich
Dec 30, 2016·Future Science OA·Mariana VarnaDidier Letourneur
Feb 19, 2016·Clinical Hemorheology and Microcirculation·A S ThummalaE A O'Rear

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.